Table 1.
Patient characteristics of all patients enrolled.
| Total no. of patients (evaluable for response) | 19 (18) |
| Sex (female/male) | 11/8 |
| Age, median (range) | 63 (30–83) |
| Performance status (WHO) | |
| 0 | 1 (5%) |
| 1 | 12 (63%) |
| 2 | 6 (32%) |
| Tumor site | |
| Gallbladder | 3 (16%) |
| Intrahepatic bile ducts | 9 (47%) |
| Extrahepatic bile ducts | 7 (37%) |
| Site of metastasis | |
| Liver | 9 (47%) |
| Lung | 2 (11%) |
| Lymph nodes | 5 (26%) |
| Peritoneum | 2 (11%) |
| Recurrence after previous surgical resection | 4 (21%) |
| Pre-treatment requiring stent or percutaneous transhepatic drainage because of obstructive jaundice | 7 (37%) |
| Pre-treatment chemistries | |
| Total bilirubin (mg/dl) | |
| Median | 0,7 |
| Range | 0,3–2,3 |
| Gamma-glutamyltransferase (<66 U/La) | |
| Median | 159 |
| Range | 34–671 |
| Aspartate aminotransferase (10–50 U/la) | |
| Median | 29 |
| Range | 8–145 |
| CA19-9 (<32 U/mLa) | |
| Median | 387 |
| Range | 4-1244000 |
a normal levels